Mirae is building a new model for managing autoimmune disease and other complex chronic conditions, starting with inflammatory bowel disease. The company's conversational AI turns everyday patient input into structured, longitudinal insight, enabling earlier intervention and more informed treatment decisions. Developed in collaboration with researchers at the University of Oxford and designed for integration into clinical workflows, Mirae connects patient experience, clinical data, and peer-reviewed evidence into a continuous system of care. By extending the reach of specialty medicine beyond episodic visits, Mirae aims to make high-quality, data-driven care more consistent, more responsive, and more accessible across patient populations
Mirae
- Health
- London, United Kingdom
- £4m
- miraehealth.com
- Update Information
More venture news
- 29 Jul 2026

MiraeMirae lands £4m in funding from Oxford Science Enterprises for conversational AI platform that tracks autoimmune disease between clinic visits
EquityHealth - 24 Jul 2026

TidalSenseTidalSense secures £14m in funding from VCs to roll out AI-driven breath test for lung disease
EquityHealth - 16 Jul 2026

BeCertainBeCertain raises a £1.7m pre-seed round led by Sure Valley Ventures for AI software that helps dentists interpret X-rays
Pre-seedHealth
